Výsledky vyhledávání

Mutation-Guided Vaccine Design: A Strategy for Developing Boosting Immunogens for HIV Broadly Neutralizing Antibody Induction

A major goal of HIV-1 vaccine development is induction of broadly neutralizing antibodies (bnAbs). While success has been achieved in initiating bnAb B cell lineages, design of boosting immunogens that select for bnAb B cell receptors with improbable

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8ec35f9fb922ae004a0cb0bdff7183c8
https://doi.org/10.1101/2022.11.11.516143

Zobrazit plný text záznamu

SARS-CoV-2 vaccination induces neutralizing antibodies against pandemic and pre-emergent SARS-related coronaviruses in monkeys

Publikováno v: bioRxiv

SUMMARYBetacoronaviruses (betaCoVs) caused the severe acute respiratory syndrome (SARS) and Middle East Respiratory Syndrome (MERS) outbreaks, and now the SARS-CoV-2 pandemic. Vaccines that elicit protective immune responses against SARS-CoV-2 and be

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7849ac2671cd4a5cdd07c8df6f443fbc
https://doi.org/10.1101/2021.02.17.431492

Zobrazit plný text záznamu

Rapid selection of HIV envelopes that bind to neutralizing antibody B cell lineage members with functional improbable mutations

Autor: Kevin Wiehe, Shi-Mao Xia, Brianna Rhodes, Barton F. Haynes, Robert Parks, Olivia Swanson, Aja Sanzone, Mattia Bonsignori, Bob C. Lin, Avivah Wang, Kevin O. Saunders, Mihai L. Azoitei, Melissa Cooper, Mark K. Louder, Nicole A. Doria-Rose

SummaryElicitation of broadly neutralizing antibodies (bnAbs) by an HIV vaccine will involve priming the immune system to activate antibody precursors, followed by boosting immunizations to select for antibodies with functional features required for

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::395fd7857a0c286b6d3ff29bd4cbd497
https://doi.org/10.1101/2021.01.04.425252

Zobrazit plný text záznamu

The functions of SARS-CoV-2 neutralizing and infection-enhancing antibodies in vitro and in mice and nonhuman primates

Autor: Ian N. Moore, Priyamvada Acharya, C. Todd DeMarco, Megan Kopp, Maggie Barr, Andrew N. Macintyre, Sophie M. C. Gobeil, Chuancang Jiang, Ralph S. Baric, Alexandra Schäfer, Derek W. Cain, M. Anthony Moody, Bianca M. Nagata, David R. Martinez, Kevin W. Bock, Robert Parks, Kartik Manne, Laura L. Sutherland, Thomas N. Denny, I-Ting Teng, Victoria Gee-Lai, Giovanna Hernandez, S. Munir Alam, Margaret Deyton, Xiaozhi Lu, John R. Mascola, Dapeng Li, Aaron G. Schmidt, Lautaro G. Perez, Christopher W. Woods, Charlene McDanal, Jared Feldman, Aja Sanzone, Ken Cronin, Barney S. Graham, Katarzyna Janowska, Robert A. Seder, Timothy M. Caradonna, Katayoun Mansouri, Kedamawit Tilahun, Barton F. Haynes, Esther J. Lee, Erica Stover, Elizabeth Petzold, Mahnaz Minai, Tarra Von Holle, Kevin Wiehe, Longping V. Tse, David C. Montefiori, Thomas H. Oguin, Victoria Stalls, Robert J. Edwards, Kevin O. Saunders, Fangping Cai, Trevor Scobey, Blake M. Hauser, Mark G. Lewis, Gregory D. Sempowski, Tongqing Zhou, Andrew Foulger, Peter D. Kwong, Hanne Leth Andersen

Publikováno v: bioRxiv

SummarySARS-CoV-2 neutralizing antibodies (NAbs) protect against COVID-19. A concern regarding SARS-CoV-2 antibodies is whether they mediate disease enhancement. Here, we isolated NAbs against the receptor-binding domain (RBD) and the N-terminal doma

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eecf5dfbdb9b3dd3dce1ff3a44ada9e3
https://doi.org/10.1101/2020.12.31.424729

Zobrazit plný text záznamu

Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses

Autor: Hanne Leth Andersen, Hana Golding, Matthew Gagne, Robert J. Edwards, Kevin O. Saunders, Barton F. Haynes, Mihai L. Azoitei, Kartik Manne, Gregory D. Sempowski, Dapeng Li, Thomas N. Denny, Esther J. Lee, C. Todd DeMarco, Robert A. Seder, Elizabeth Petzold, Priyamvada Acharya, Surender Khurana, Mahnaz Minai, Mark G. Lewis, Trevor Scobey, R. Wes Rountree, Sophie M. C. Gobeil, Anyway B. Kapingidza, Thomas H. Oguin, Christopher W. Woods, Madison Berry, Rachel L. Spreng, Drew Weissman, Juanjie Tang, Mark A. Tomai, Christopher B. Fox, Ian N. Moore, Laura L. Sutherland, Kevin Wiehe, Ralph S. Baric, Robert Parks, Fangping Cai, Katayoun Mansouri, Norbert Pardi, Kevin W. Bock, Longping V. Tse, Daniel C. Douek, David R. Martinez, David C. Montefiori, Bianca M. Nagata, Aja Sanzone, Maggie Barr, S. Munir Alam, Haiyan Chen

Publikováno v: Signal Transduction and Targeted Therapy
Nature

Betacoronaviruses caused the outbreaks of severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome, as well as the current pandemic of SARS coronavirus 2 (SARS-CoV-2)1-4. Vaccines that elicit protective immunity against SARS-CoV-

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a21d8feaf8225d5d115fd14e1099ae83

Zobrazit plný text záznamu

In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies

Autor: Mark G. Lewis, Andrew N. Macintyre, Robert Parks, Fangping Cai, S. Munir Alam, Dapeng Li, Trevor Scobey, Alexandra Schäfer, Timothy M. Caradonna, C. Todd DeMarco, Kevin W. Bock, Ian N. Moore, Kedamawit Tilahun, Charlene McDanal, Thomas H. Oguin, I-Ting Teng, Priyamvada Acharya, Andrew Foulger, Tarra Von Holle, Elizabeth Petzold, Longping V. Tse, Christopher W. Woods, Megan Kopp, Robert J. Edwards, Bianca M. Nagata, Mahnaz Minai, M. Anthony Moody, Thomas N. Denny, Victoria Gee-Lai, John R. Mascola, Sophie M. C. Gobeil, Kevin Wiehe, Lautaro G. Perez, Tongqing Zhou, Chuancang Jiang, Kevin O. Saunders, David C. Montefiori, Aja Sanzone, Erica Stover, Katarzyna Janowska, Kartik Manne, Gregory D. Sempowski, Peter D. Kwong, Barton F. Haynes, Blake M. Hauser, Wes Rountree, Derek W. Cain, David R. Martinez, Barney S. Graham, Maggie Barr, Esther J. Lee, Ralph S. Baric, Kenneth D. Cronin, Margaret Deyton, Victoria Stalls, Xiaozhi Lu, Jared Feldman, Katayoun Mansouri, Hanne Leth Andersen, Laura L. Sutherland, Giovanna Hernandez, Robert A. Seder, Yunfei Wang, Aaron G. Schmidt

Publikováno v: Cell

SARS-CoV-2-neutralizing antibodies (NAbs) protect against COVID-19. A concern regarding SARS-CoV-2 antibodies is whether they mediate disease enhancement. Here, we isolated NAbs against the receptor-binding domain (RBD) or the N-terminal domain (NTD)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1991d4b67491ac07d0d4d3550e829db6
https://doi.org/10.1016/j.cell.2021.06.021

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání